On the 8th, Medinet announced that the Taiwan regulatory authority has approved the provision of gamma delta T cell therapy in new medical institutions.
The company has signed a licensing agreement with Medigen Biotechnology Corporation (MBC), a company listed on the Taipei Stock Exchange, for its gamma delta T cell culture processing technology targeting cancer. The technology transfer of this technology has been completed. So far, seven medical institutions in Taiwan have obtained approval from the regulatory authorities, and one of them has started offering cancer immunocell therapy using this technology. However, the regulatory authorities in Taiwan have approved a new medical institution (eighth facility) for the provision of cancer immunocell therapy using this technology.
The approved medical institution this time is the Taipei Municipal Wanfang Hospital, which is a partner medical institution of MBC. In the future, MBC aims to promote the use of this technology for immunocell therapy for cancer in Taiwan. Under the license agreement, the company will receive royalties based on the number of gamma delta T cells cultured by MBC.